Applied Therapeutics Inc. - APLT

Applied Therapeutics Inc. – APLT

APLT Investors Who Have Suffered Financial Losses Encouraged To Contact Kehoe Law Firm, P.C.

Kehoe Law Firm, P.C. is investigating whether Applied Therapeutics, Inc. (“Applied Therapeutics” or the “Company”) (NASDAQ: APLT) violated federal securities laws.

APPLIED THERAPEUTICS INVESTORS WITH FINANCIAL LOSSES ARE ENCOURAGED TO COMPLETE KEHOE LAW FIRM’S SECURITIES CLASS ACTION QUESTIONNAIRE.

Investors of Applied Therapeutics should be aware that on January 3, 2022, Applied Therapeutics advised that “[f]ollowing discussions with the FDA at the end of the year, the Company has decided to hold on submitting an NDA for AT-007 for treatment of Galactosemia pending additional discussions with the agency. Although the Galactosemia program had previously been discussed in the context of an NDA for Accelerated Approval based on reduction in galactitol, the FDA has now indicated that clinical outcomes data will likely be required for approval.”

On this news, the stock price of Applied Therapeutics was down pre-market on January 3, 2021 more than 25%.

APPLIED THERAPEUTICS INVESTORS WITH FINANCIAL LOSSES ARE ENCOURAGED TO CONTACT JOHN KEHOE, ESQ., (215) 792-6676, EXT. 801, [email protected], [email protected], TO DISCUSS THE APPLIED THERAPEUTICS SECURITIES CLASS INVESTIGATION OR POTENTIAL LEGAL CLAIMS.
Kehoe Law Firm, P.C.